-+ 0.00%
-+ 0.00%
-+ 0.00%

Maxim Group Maintains Buy on Chemomab Therapeutics, Raises Price Target to $7

Benzinga·02/20/2025 18:26:19
Listen to the news
Maxim Group analyst Michael Okunewitch maintains Chemomab Therapeutics (NASDAQ:CMMB) with a Buy and raises the price target from $4 to $7.